How ADAMAS used Cyntegrity’s Risk Analytics to Focus QA Effort in a Global Phase III Oncology Study
In complex late-phase oncology trials, inspection readiness depends on how early and accurately study teams can identify true risk signals. In a recent collaboration, ADAMAS Consulting combined its expert QA strategies with Cyntegrity’s AI-augmented risk analytics to remotely assess data quality across multiple investigator sites in a global Phase III oncology program.
Using Cyntegrity’s MyRBQM® Portal, ADAMAS was able to proactively identify high-risk sites early in the process, aligning their QA approach with ICH E6(R3) principles. Through expert-led strategy and advanced analytics, data from 50 investigator sites were centrally monitored, helping to detect site-specific risks earlier and trigger timely corrective actions.
This targeted, scalable model not only optimized QA resource allocation but also improved inspection outcomes and sponsor confidence.
Key Takeaways
- How targeted risk indicators guide proportionate oversight at scale
- Where central monitoring and remote data review accelerate corrective actions
- Practical patterns to strengthen inspection outcomes in complex oncology trials
👉 Download the Full ADAMAS Case Study
Discover how ADAMAS helped a leading pharmaceutical sponsor prepare for inspection using a targeted risk-based approach: Click here!
Stay Ahead of ICH E6(R3) Compliance
Visit ADAMAS ICH E6(R3) Hub for expert insights, practical tools, and strategic guidance to prepare your team for the future of GCP.
Cyntegrity provides AI-augmented RBQM technology via MyRBQM® Portal, while ADAMAS contributes deep QA expertise. Together, they empower oncology study sponsors to detect risks earlier, act faster, and approach inspections with confidence.
